Evolus Earnings Call Signals Growth Amid Headwinds

Evolus, Inc. ((EOLS)) has held its Q4 earnings call. Read on for the main highlights of the call.

Evolus, Inc. struck an optimistic tone on its latest earnings call, pairing another year of double‑digit revenue growth with a clear roadmap to profitability. Management acknowledged macro and competitive headwinds but emphasized disciplined expense control, margin resilience, and a growing aesthetics portfolio as key levers to drive sustainable, profitable expansion through 2026 and beyond.

Top-Line Growth — Full Year and Q4

Evolus delivered 2025 global net revenue of $297.2 million, up 12% year over year and marking its sixth straight year of double‑digit growth. Fourth‑quarter revenue rose even faster, climbing 14% to $90.3 million and underscoring the company’s ability to expand despite a softening U.S. aesthetics market.

Jeuveau Market Performance

Jeuveau remained the growth engine, generating $83.1 million of revenue in the fourth quarter and expanding its U.S. toxin share to more than 14%. The brand continued to gain traction even as overall injectable procedure volumes declined, highlighting strong customer loyalty and effective commercial execution against larger incumbents.

Evolysse Launch Momentum

The Evolysse filler line, the first new HA technology in over a decade, continued its early ramp with more than 3,000 customers purchasing to date and $7.2 million in Q4 revenue. Management framed 2026 as a key inflection year, with broader sampling planned in the second quarter and the Sculpt indication expected to secure U.S. approval in the fourth quarter.

International Expansion

Outside the U.S., Evolus nearly doubled international revenue, which climbed to roughly 8% of global sales in 2025 from 5% the prior year. The company now operates in nine countries and is nearing a double‑digit toxin market share in the U.K., signaling meaningful whitespace for further global growth.

Healthy Gross Margins

Gross profitability held up well, with reported gross margin around 66% and adjusted gross margin approximately 67% for both the quarter and full year. This stability came despite product mix shifts from the Evolysse rollout and tariff impacts, giving management confidence that margins can be maintained as the portfolio broadens.

Operating Leverage and Profitability Trajectory

Non‑GAAP operating expenses fell 4% in the second half of 2025 versus the first, supporting Q4 non‑GAAP operating income of $7.1 million, up from $6.7 million a year earlier. Evolus reiterated its goal of achieving full‑year profitability in 2026 with a low‑ to mid‑single‑digit adjusted EBITDA margin and is targeting $450–$500 million of revenue and 13%–15% EBITDA margins by 2028.

Strong Cash and Liquidity Actions

The cash balance improved to $53.8 million at year‑end from $43.5 million in the third quarter, bolstered by solid operations and tighter working capital. Evolus also added a new revolving credit facility of up to $30 million, plus an accordion option and access to two additional $50 million debt tranches, enhancing liquidity without leaning on equity issuance.

Customer Retention and Marketing Programs

On the demand side, the Evolus Rewards program surpassed 1.4 million treated patients, reinforcing patient stickiness and repeat usage. New practice‑focused initiatives like the Evolux co‑branded media offering and portfolio growth rebates are deepening account relationships and contributed to stronger provider commitment late in the year.

Challenging Aesthetics Market

Management was candid that 2025 was one of the toughest years for U.S. injectables, with aesthetic procedure volumes falling for only the third time in 25 years. Evolus estimates the neurotoxin market declined in the mid‑ to upper‑single digits and expects ongoing pressure in fillers, modeling a low single‑digit decline in that category for 2026.

GAAP Operating Expense Increases

While non‑GAAP costs were managed tightly, GAAP operating expenses rose to $229.8 million in 2025 from $216.7 million a year earlier. The bulk of the increase came from SG&A, which climbed to $220.8 million as the company invested in the Evolysse launch and international infrastructure to support long‑term growth.

Tariff Headwinds on Evolysse

Evolysse imports from France are currently classified as medical devices and subject to a 10% tariff, with the company effectively modeling a 15% rate in its 2025 results and 2026 outlook. These duties create incremental cost pressure and add some uncertainty to margin planning, particularly as Evolysse grows as a share of the overall portfolio.

Short-Term Expense Timing and Non-GAAP Variability

Non‑GAAP operating expenses ticked up sequentially to $53.0 million in Q4 from $49.7 million in Q3, driven largely by the timing of customer events and commercial spend. Management also highlighted that non‑GAAP adjustments such as stock‑based compensation, royalty revaluation, and restructuring costs can cause quarter‑to‑quarter variability, complicating comparisons.

Competitive Risk — New Entrants in 2026

The company is preparing for a more crowded toxin landscape as new products like AbbVie’s BoNT/E and Galderma’s liquid toxin are expected to debut in 2026. Evolus anticipates increased sampling and promotional intensity as rivals seek early adoption and has baked this near‑term pressure into its 2026 growth and margin assumptions.

Moderate Cash Position With Continued Uses

Despite progress on liquidity, management described the cash position as moderate given planned investments and interest obligations. In 2026, cash use will reflect $16–$17 million of interest expense and spending tied to the Evolysse Sculpt launch, including inventory build and milestone payments, with debt facilities providing incremental working capital support.

Evolysse Still Early-Stage Adoption

Evolysse remains in the early innings despite an encouraging base of more than 3,000 purchasing accounts, as many customers are still measured in stocking levels. Management indicated that wider adoption will require more sampling and training sessions, which could temporarily temper near‑term upside while building a broader, more durable user base.

Conservative 2026 Revenue Guide

Reflecting macro softness and heightened competition, Evolus issued a cautious 2026 revenue outlook of $327–$337 million, implying 10%–13% growth. The guidance is below its long‑term growth aspirations but is framed as a realistic baseline that factors in market declines, tariff assumptions, and the impact of new toxin launches.

Forward-Looking Guidance and Profitability Outlook

For 2026, Evolus forecasts net revenue of $327–$337 million with Evolysse and Estyme contributing 10%–12% of sales and adjusted gross margin between 65.5% and 67%. Non‑GAAP operating expenses are expected at $210–$216 million, supporting the company’s plan to reach full‑year profitability with a low‑ to mid‑single‑digit adjusted EBITDA margin and longer‑term goals of $450–$500 million revenue and double‑digit margins by 2028.

Evolus’ latest update paints the picture of a focused challenger brand that is growing through a cyclical slowdown while investing for scale. Investors will be watching whether Jeuveau can keep taking share, Evolysse can move from early adoption to mainstream use, and management can deliver on its 2026 profitability pledge in a tougher and more crowded aesthetics market.